SEOM clinical guidelines for endometrial cancer (2017)

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Cita:

Santaballa, A. (Ana); Matías-Guiu, X. (Xavier); Redondo, A. (Alba); et al. "SEOM clinical guidelines for endometrial cancer (2017)". Clinical and translational oncology. 20 (1), 2018, 29 - 37

Resumen

Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defned and there are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment. Advances in the knowledge of the molecular abnormalities in EC have permitted the development of promising targeted therapies.

URI :

https://hdl.handle.net/10171/65692

DOI:

10.1007/s12094-017-1809-9

Aparece en las colecciones:

DA - CUN - Oncología médica - Artículos de revista

Ficheros en este ítem: